145085 - Has the EU incentive for drug repositioning been effective.pdf (440.9 kB)
Has the EU incentive for drug repositioning been effective? An empirical analysis of the “+1” regulatory exclusivity
journal contribution
posted on 2023-05-21, 00:22 authored by Johnathon LiddicoatJohnathon Liddicoat, Liddell, K, Aboy, M, Wested, JEU law incentivises drug marketing authorisation holders (MAHs) to find new uses for their compounds (research known as “repositioning”) by offering them an extra year of market protection if the new use is authorised. This extra year, known as the “+1”, was enacted on limited evidence, and no study has examined its effect since it began. Yet, several leading commentators suggest lengthening the +1. This study assesses the effectiveness of the +1 by analysing all the relevant instances of MAHs repositioned their drugs before and after the +1 came into effect. The results show that: i) 42.2% of MAHs repositioned their drugs before the +1 came into effect, and ii) once the +1 did come into effect, it did not increase the percentage of MAHs that repositioned their drugs. This study finds that the +1 failed to increase repositioning and then proceeds to consider reform options, including repealing the law. In doing so, this study takes the first steps towards an evidence-based policy for the topic.
History
Publication title
IIC - International Review of Intellectual Property and Competition LawVolume
52Issue
7Pagination
825-851ISSN
0018-9855Department/School
Faculty of LawPublisher
SpringerPlace of publication
GermanyRights statement
Copyright The Author(s) 2021. Post-prints are subject to Springer Nature re-use terms.Repository Status
- Restricted